A First-in-Human, Ascending-Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single, Subcutaneous Dose of LY3209590
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs LY 3209590 (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 03 Nov 2017 Status changed from recruiting to completed.
- 21 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
- 21 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.